Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $26.79 USD
Change Today -0.14 / -0.52%
Volume 313.9K
DEPO On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 11:56 AM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

depomed inc (DEPO) Snapshot

Open
$26.51
Previous Close
$26.93
Day High
$27.15
Day Low
$26.51
52 Week High
07/21/15 - $33.74
52 Week Low
09/5/14 - $13.47
Market Cap
1.6B
Average Volume 10 Days
1.3M
EPS TTM
$0.84
Shares Outstanding
60.3M
EX-Date
--
P/E TM
32.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for DEPOMED INC (DEPO)

depomed inc (DEPO) Related Businessweek News

No Related Businessweek News Found

depomed inc (DEPO) Details

Depomed, Inc., a specialty pharmaceutical company, develops products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. The company is involved in the clinical development of IW-3718 refractory gastroesophageal reflux disease program using Acuform drug delivery technology. Depomed, Inc. sells its Gralise products to wholesalers and retail pharmacies. The company also has a portfolio of royalty and milestone producing license agreements based on its proprietary Acuform gastroretentive drug delivery technology with Mallinckrodt Inc.; Ironwood Pharmaceuticals, Inc.; and Janssen Pharmaceuticals, Inc. The company was founded in 1995 and is headquartered in Newark, California.

324 Employees
Last Reported Date: 02/26/15
Founded in 1995

depomed inc (DEPO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $620.1K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $374.8K
Senior Vice President and General Counsel
Total Annual Compensation: $396.6K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $211.9K
Senior Vice President of Business Development
Total Annual Compensation: $316.7K
Compensation as of Fiscal Year 2014.

depomed inc (DEPO) Key Developments

Horizon Pharma, Inc. Files Lawsuit Against Depomed and the Members of its Board of Directors

Horizon Pharma Inc. filed a lawsuit in the Superior Court of the State of California, County of Santa Clara, naming as defendants Depomed Inc. and the members of its board of directors, Vicente J. Anido, Jr., Karen A. Dawes, Louis J. Lavigne, Jr., Samuel R. Saks, James A. Schoeneck, Peter D. Staple and David B. Zenoff. The lawsuit alleged that the adoption by the Depomed Board of the Rights Agreement dated as of July 12, 2015 between Depomed and Continental Stock Transfer & Trust Company, as Rights Agent, and Sections 2(b), 2(c), 2(d), and 5(d) of Depomed's amended and restated bylaws, effective July 12, 2015, violates the General Corporation Law of the California Corporations Code, constitutes ultra vires acts and breaches the fiduciary duties of the members of the Depomed Board. The lawsuit seeks, among other things, an order (i) declaring that the Rights Agreement and Sections 2(b), 2(c), and 2(d) of the Bylaws are invalid under California law, (ii) declaring that the members of the Depomed Board breached their fiduciary duties by enacting the Rights Agreement and Sections 2(b), 2(c), 2(d), and 5(d) of the Bylaws, (iii) enjoining the members of the Depomed Board from relying on, implementing, applying or enforcing either the Rights Agreement or Sections 2(b), 2(c), 2(d), or 5(d) of the Bylaws, (iv) enjoining the members of the Depomed Board from taking any improper action designed to impede, or which has the effect of impeding, the proposal by Horizon Pharma to acquire Depomed in an all-stock transaction or the efforts of Horizon Pharma to acquire control of Depomed and (v) compelling the members of the Depomed Board to redeem the Rights Agreement or to render it inapplicable to Horizon Pharma.

DepoMed Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revises Earnings Guidance for the Year 2015 and 2016

DepoMed Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $94.504 million compared to $67.732 million, loss from operations of $17.214 million compared to income from operations of $26.55 million and net loss of $21.7 million or $0.36 per basic and diluted share compared to net income of $12.75 million or $0.21 per diluted share for the last year. Non-GAAP adjusted earnings were $20.002 million or $0.27 per share compared to $0.32 million or $0.01 per share in last year. For the six months, the company reported total revenues of $126.1 million compared to $144.3 million, loss from operations of $27.1 million compared to income from operations of $62.3 million and net loss of $33.3 million or $0.56 per basic and diluted share compared to net income of $30.7 million or $0.51 per diluted share for the last year. Non-GAAP adjusted earnings were $12.001 million or $0.19 per share compared to loss of $0.5 million or $0.01 per share in last year. The company revised earnings guidance for the year 2015 and 2016. For the year, the company now expects total product sales of $320 million to $335 million against previous guidance of $310 million to $335 million, non-GAAP adjusted earnings of $40 million to $45 million against previous guidance of $16 million to $28 million and adjusted EBITDA of $95 million to $100 million against previous guidance of $85 million to $100 million. The company expects total revenues to be approximately the same as the company not anticipating any milestone revenue in 2015. Operating expense, exclusive of amortization, is expected to be $195 million to $210 million. This is not a change from previous guidance. Intangible asset amortization is expected to be approximately $84 million, reflecting amortization of the NUCYNTA, CAMBIA, Lazanda and Zipsor acquisitions. Interest expense for the year is expected to be $68 million. This reflects the cash and noncash interest expense on the convertible debt for the full year and the interest expense for nine months on the high-yield debt that the company raised in order to finance the balance of the NUCYNTA purchase price. With respect to the company's effective tax rate, the company expects tax rate to be negative this year as a result of the tax refund. For 2016, the company expects to pay an effective tax rate in the mid-teens. Adjusted EBITDA is expected to be $95 million to $110 million. This reflects an increase of $10 million from the company's previous guidance.

DepoMed Inc. to Report Q2, 2015 Results on Jul 29, 2015

DepoMed Inc. announced that they will report Q2, 2015 results at 4:30 PM, US Eastern Standard Time on Jul 29, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DEPO:US $26.79 USD -0.14

DEPO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Acorda Therapeutics Inc $32.38 USD +0.41
Emergent BioSolutions Inc $33.41 USD +0.12
Insys Therapeutics Inc $33.99 USD +1.57
Nektar Therapeutics $11.08 USD +0.03
Supernus Pharmaceuticals Inc $18.33 USD +0.18
View Industry Companies
 

Industry Analysis

DEPO

Industry Average

Valuation DEPO Industry Range
Price/Earnings 27.7x
Price/Sales 4.6x
Price/Book 4.9x
Price/Cash Flow 16.8x
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DEPOMED INC, please visit www.depomedinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.